Posts by Sandra Ansanay-Alex
Annaida Technologies SA closes oversubscribed Pre-Series A
Annaida Technologies, a Vaud-based start-up company bringing magnetic resonance to the scale of cells, announces the successful closing of its oversubscribed Pre-Series A funding round. The round, led by HEMEX, saw the participation from existing investors including Zürcher Kantonalbank (ZKB), Excellis, EFI Lake Geneva Ventures, and members of Club degli Investitori through Simon…
Read MoreAdoram Therapeutics Secures CHF 1 Million Grant from Innosuisse
Adoram Therapeutics has secured a CHF 1.05 million grant from Innosuisse to propel its groundbreaking anti-inflammatory programme, aiming to develop safer and more effective therapies. Adoram Therapeutics is a University of Geneva (UNIGE) spinoff specializing in allosteric modulators for cancer immunotherapy and inflammatory conditions. The Innosuisse Grant will allow the research will be…
Read More4 Swiss Start-Ups join Tech4Eva
Tech4Eva, Switzerland’s first start-up acceleration programme dedicated to women’s health (FemTech), has kicked off its fifth edition with a record-breaking 195 applications from 42 countries. Among the 16 start-ups selected for this year’s 6-month program, four promising companies hail from Switzerland—further underscoring the country’s growing role in this dynamic sector. This year’s Swiss cohort includes:…
Read MoreDigeHealth supported by FIT
DigeHealth is an EPFL Spinoff detecting post-operative complications using a device to analyse intestinal sounds and just received a CHF 100,000 Tech Seed loan from FIT, Fondation pour l’Innovation Technologique. In the post-operative period, a significant proportion of patients experience intestinal complications, such as post-operative ileus or intestinal obstruction. If not detected in time,…
Read MoreH4: A Pragmatic Hub for Health and Care Innovation
In a world where the challenges of the health and care sectors are multiplying, H4 positions itself as a unique innovation hub in Lausanne, Switzerland. Through its pragmatic and collaborative approach, H4 supports groundbreaking projects and accelerates the development of impactful and sustainable solutions. Since its creation in 2022, with the support of the Fondation…
Read MoreHAYA Therapeutics Raises $65 Million in Series A Funding
The Series A round is led by Sofinnova Partners and Earlybird Venture Capital with syndicate including Eli Lilly and Company. The funding will help advance clinical development of heart failure lead candidate and expand platform targeting the regulatory genome. HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics that reprogram…
Read MoreCarewell Wins the 2025 PERL Trophy
The 23rd edition of the Prix Entreprendre Lausanne Région (PERL) took place on Wednesday 7 May, at Beaulieu-Lausanne, gathering around 300 leaders from politics, business, and academia. The prestigious Lausanne Région Trophy, worth CHF 50,000, was awarded to Carewell, a company based in Pully, for its innovative project at the intersection of technology and social…
Read MoreSwiss Medical Network joins the Mayo Clinic Care Network
Swiss Medical Network (Vaud – Switzerland) and Mayo Clinic are proud to announce that seven clinics and centres of Swiss Medical Network have joined the Mayo Clinic Care Network, becoming the first healthcare provider in Western Europe to enter the collaboration. The agreement includes Clinique de Genolier, Privatklinik Bethanien in Zurich, Clinica Sant’Anna in Lugano…
Read MoreSwiss Biotech Sector Shows Strength and Growth in 2024
Despite a challenging global market environment, the Swiss biotech sector once again demonstrated strength and resilience in 2024, as detailed in the newly released 2025 Swiss Biotech Report presented on 5 May 2025 during the Swiss Biotech Days. Co-authored by the Swiss Biotech Association, EY, and eight partner organizations, the report offers a deep dive…
Read MoreOncoSwab Secures CHF 1.3 Million Innosuisse Grant to Advance Lung Cancer Early Detection
OncoSwab, a Jura-based startup pioneering non-invasive cancer diagnostics, has secured a CHF 1.3 million Innosuisse grant to fund upcoming clinical trials in partnership with Inselspital Bern. The grant will enable OncoSwab to accelerate the clinical validation of its nasal fluid-based biomarker test — a revolutionary approach to the early detection of lung cancer. Addressing…
Read More